成都先导药物开发股份有限公司 CHENGDU HITGEN LTD Mediaroom

ESG | HitGen Releases 2025 Sustainability Report

CHENGDU, China, April 29, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. (...

2026-04-29 19:00 3562

HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)

CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- HitGen Inc. (hereinafter referred to as "HitGen", SSE...

2025-12-15 22:30 2657

HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases

* Company enters into new agreement with the Gates Foundation to identify novel drug leads target...

2025-11-20 22:30 1664

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

* BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compoun...

2025-09-15 21:30 2339

Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Deve...

2025-08-27 21:30 2112

Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

ESG | HitGen Releases Its Inaugural Sustainability Report

CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("H...

2025-07-04 19:00 4977

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery p...

2024-08-22 21:30 3337

Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks

CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Appl...

2024-07-16 23:55 3160

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology ...

2024-02-20 22:30 2662

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. (...

2023-09-28 21:30 2490

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...

2023-08-10 21:30 2913

HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research

CHENGDU, China, June 26, 2023 /PRNewswire/ -- HitGen Inc. ("HitGen", SSE: 688222.SH) has recently l...

2023-06-26 21:30 3274

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("H...

2023-05-18 21:30 3245

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...

2022-12-12 10:10 2663

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vern...

2022-09-28 16:00 2344

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives

CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidi...

2022-09-05 16:00 3373

Latest News